-
May 29, 2012, 02:00 AM
by
Michael Croft
Bio-IT World | A summary of the new products in bio-IT released in the past month including NGS sample prep, cloud storage-as-a-service, clinical trial document management, and more.
Full story
-
May 25, 2012, 03:00 AM
by
Michael Croft
Winnipeg Free Press | Canadian researchers screened about 3,000 compounds looking for those that would selectively inhibit cancer stem cells. Of the 20 promising results, one was the antipsychotic drug thioridazine.
Full story
-
May 24, 2012, 07:00 AM
by
Michael Croft
Bio-IT World | The Singapore National Research Foundation (NRF) Fellowship has released the call for applicants for the sixth annual Singapore NRF Fellowship. The fellowship consists of a five-year research grant of up to $2.4 million to an individual, for research undertaken in Singapore. Fellowship proposals are due by August 15, 2012.
Full story
-
May 24, 2012, 02:00 AM
by
Michael Croft
Bloomberg | In light of a small set of data, Amgen is reviving its gastric cancer drug rilotumumab that seems to show efficacy for patients with high levels of c-Met, a protein linked to cancer growth. The revival is a win for personalized medicine.
Full story
-
May 24, 2012, 01:00 AM
by
Michael Croft
CNN | The American College of Obstetricians and Gynecologists released its recommendation this week that personalized genetic tests be only used in a clinical trial setting, saying the tests are not "ready for prime time."
Full story
-
May 24, 2012, 01:00 AM
by
Michael Croft
Xconomy | Ra Pharmaceuticals is announcing its technology platform to develop protein-like molecules that it calls Cyclomimetrics. The technology was licensed from Uppsala University in Sweden, and makes large molecules that can be made into pills.
Full story
-
May 23, 2012, 18:00 PM
by
Michael Croft
Bio-IT World | With a recent rebranding and evolving business model, Selventa—the company formerly known as Genstruct—has decided to release a key knowledge engineering asset to the scientific community.
Full story
-
May 23, 2012, 04:00 AM
by
Michael Croft
New York Times | Genentech's new Alzheimer's drug trial will test the drug on 200 patients with a genetic mutation for early-onset disease (with half receiving placebo) and another 100 family members without the mutation.
Full story
-
May 22, 2012, 06:00 AM
by
Michael Croft
Bio-IT World | The National Center for Supercomputing Applications (NCSA) has selected T-Finity tape libraries from Boulder, CO-based Spectra Logic to provide hundreds of petabytes of data storage for its upcoming Blue Waters supercomputing system, one of the most powerful supercomputing systems in the world.
Full story
-
May 22, 2012, 01:00 AM
by
Michael Croft
eCliniqua | The tedious process of building an electronic clinical trial is a stubborn bottleneck requiring too much time and too many resources. Those are the topline results of a 2011 survey conducted at two annual meetings—the Drug Information Association (DIA) and the Society for Clinical Data Management (SCDM). Cmed Technology, a UK-based provider of eClinical solutions developed and administered the survey, which resulted in 87 respondents from 55 companies.
Full story
-
May 21, 2012, 12:40 PM
by
Michael Croft
Bio-IT World | The Smithsonian Institution in Washington, D.C., is planning a “high-tech, high-intensity” museum exhibition next year to mark the 10th anniversary of the official completion of the Human Genome Project, with millions of dollars pledged already by the Life Technologies Foundation, the Brin Wojcicki Foundation, and other donors.
Full story
-
May 21, 2012, 04:00 AM
by
Michael Croft
Scientific American | First there was GINA, now GIPA? The Genetic Information Privacy Act, currently under consideration by California lawmakers, would require an individual's written consent for the collection, analysis, or sharing of any genetic information.
Full story
-
May 21, 2012, 00:05 AM
by
Michael Croft
Zacks | Accelrys has bought a Cloud-based drug discovery and development platform from SCYNEXIS, completing the contract both companies entered into last year.
Full story
-
May 21, 2012, 00:05 AM
by
Michael Croft
Bloomberg | In a paper released last week in Science, researchers at the University of Washington show that most genetic variations in people are rare and evolutionarily recent. The findings further reinforce the changes being made to how we think about correlating genetic changes with diseases.
Full story
-
May 18, 2012, 01:00 AM
by
Michael Croft
New York Times | Human Genome Sciences is still rejecting a bid from GlaxoSmithKline to buy the biotech. Human Genome Sciences' board voted unanimously to reject the GSK offer and adopt a shareholders' rights plan, or poison pill.
Full story
-
May 17, 2012, 03:00 AM
by
Michael Croft
2012 Bio-IT World Best Practices Winner | “It’s survival of the fittest,” explains Ulrich Betz, department head of Merck Serono’s Innovation & Entrepreneurship Incubator, of Merck’s innospire program, winner of the 2012 Bio-IT World Best Practices award for Knowledge Management. Only the best ideas win.
Full story
-
May 17, 2012, 02:00 AM
by
Michael Croft
Wall Street Journal | Pfizer's new lung cancer drug is showing effectiveness against childhood cancers with defects in the ALK gene.
Full story
-
May 16, 2012, 03:00 AM
by
Michael Croft
Bio-IT World | BGI has garnered a lot of attention for its sheer sequencing capacity. Now the sequencing center has installed a new Roche GS FLX+ System at its Shenzhen facility to enhance BGI's long read sequencing capabilities and supplement the short read technologies.
Full story
-
May 16, 2012, 02:05 AM
by
Michael Croft
Fox Business | GlaxoSmithKline has purchased the remaining percentage of Cellzome for about $98 million in cash.
Full story
-
May 16, 2012, 02:00 AM
by
Michael Croft
Forbes | Last year NIH set up the National Center for Advancing Translational Sciences to overcome bottlenecks and accelerate the development of diagnostics and therapeutics. Recently, the Center's mandate has been further expanded.
Full story
